Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis

  title={Long-term use of a cannabis-based medicine in the treatment of spasticity and other symptoms in multiple sclerosis},
  author={D. Wade and P. Makela and H. House and C. Bateman and P. Robson},
  journal={Multiple Sclerosis},
  pages={639 - 645}
  • D. Wade, P. Makela, +2 authors P. Robson
  • Published 2006
  • Medicine
  • Multiple Sclerosis
  • The object of this study was to monitor the safety and efficacy of long-term use of an oromucosal cannabis-based medicine (CBM) in patients with multiple sclerosis (MS). A total of 137 MS patients with symptoms not controlled satisfactorily using standard drugs entered this open-label trial following a 10-week, placebo-controlled study. Patients were assessed every eight weeks using visual analogue scales and diary scores of main symptoms, and were followed for an average of 434 days (range: 21… CONTINUE READING

    Paper Mentions

    An extension study to evaluate the long-term safety, tolerability and efficacy of GW-1000-02 treatment in multiple sclerosis.  
    ConditionsMultiple Sclerosis, Spasticity
    New approaches in the management of spasticity in multiple sclerosis patients: role of cannabinoids
    • 18
    • Open Access
    Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis
    • 14
    • Highly Influenced
    Cannabis for the Management of Pain: Assessment of Safety Study (COMPASS).
    • 105
    • Open Access
    A questionnaire survey of patients and carers of patients prescribed Sativex as an unlicensed medicine.
    • 18
    • Open Access
    Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis
    • 11
    • Highly Influenced
    Therapeutic Advances in Neurological Disorders


    Publications referenced by this paper.
    Psychiatric effects of cannabis.
    • 401
    • Open Access